Business Wire

OCEANSIX-FUTURE-PATHS-LT

Share
oceansix future paths Acquires Original RePack Oy

oceansix future paths Ltd. (“oceansix” or the “Company”), a leader in advanced recycling and manufacturing technological solutions with a presence on the TSX Venture Exchange in Toronto (TSXV: CUSIP 001194828, OSIX), in New York (OTCQB: AKMYF), and Frankfurt Stock Exchange (WKN: A3EFB0, ISIN: IL0011948283, 5FC0), is pleased to announce that today it has entered into an asset purchase agreement (the “Agreement”) pursuant to which oceansix, through its subsidiary Oceansix S.L., has purchased the business of Original RePack Oy (“RePack”), a pioneer in reusable packaging systems with a decade of proven track record (the “Acquisition”). The Acquisition will allow the Company to reduce the reliance on single-use packaging in e-commerce deliveries, which is growing exponentially and reached an annual dispatch of 161 billion parcels in 2022.

Transaction Details

The total consideration for the Acquisition, based on the Company’s current share price, is valued by the parties at CDN $2,392,912. Pursuant to the Agreement, oceansix acquired the business of RePack in exchange for: (i) issuing 24,948,840 common shares in the capital of the Company (the “Shares”) to the shareholders of RePack; and (ii) a payment of USD $108,000 (the equivalent of CDN $147,517, based on current exchange rates) (the “Cash Payment”) on closing. 15,282,176 of the Shares were issued to the shareholders of RePack on closing of the Acquisition, with the balance to be issued to the shareholders of RePack in up to four subsequent installments, selected at the option of RePack.

The Acquisition is an arm’s length transaction. All Shares issued pursuant to the Agreement will be restricted from trading for four months and one day after issuance. The Agreement and Acquisition remain subject to the final approval of the TSX Venture Exchange (the “Exchange”). The price per share of Shares issued post-closing to shareholders of RePack will be subject to the Company’s share price at their time of issuance and calculated in accordance with the rules of the Exchange.

oceansix solidifies its commitment to reshaping the packaging Industry

“As a pioneering force in sustainable innovation and disruptive engineering, our recent acquisition of RePack marks a significant milestone in our journey towards a more sustainable future,” Elad Hameiri, CEO of oceansix, states. “Together with RePack we are entering the new era where packaging is used again and again.”

A Sustainable Satisfaction. Delivered.

RePack, now a central pillar in oceansix's mission, were the first ones who introduced reusable packaging to e-commerce. Jonne Hellgren, CEO of RePack, comments: "Together, we lead the movement against single-use packaging, by creating a true circular system. "Reduce. Reuse. RePack." becomes more than a slogan—it is our operational mantra."

A New Alliance for the End of Packaging Trash

This call to action reflects oceansix and RePack's shared vision for cleaner and more efficient deliveries. Jonne Hellgren emphasizes, "With oceansix, we will be able to make sustainability simple and engaging, creating a continuous loop of good. To make this happen it takes more than just a reusable product. It needs a truly circular, scalable system.”

Rebelling Against the Status Quo

The joint mission is unequivocally defined: to make reusable packaging very simple and convenient for retailers and their customers. “This collaboration is not a startup experiment, but a mature, credible, and scalable solution to revolutionize the e-commerce packaging industry,” emphasized Elad Hameiri, CEO of oceansix. RePack’s reusable packaging, backed by oceansix's 30 years of proven business execution and innovative proprietary technology, could finally become the standard solution to e-commerce packaging and put an end to single-use packaging trash. Hameiri accentuates: "It is not just a merger, it's a rebellion against the status quo.”

RePack Initiative: Keep Packing, Stop Trashing

Learn more about how oceansix and RePack are crafting the future of e-commerce by visiting our websites at oceansix.com and RePack.com. Connect with us on LinkedIn, Instagram to join our journey towards reducing packaging waste and creating more sustainable and engaging consumer experiences.

About oceansix

oceansix future paths Ltd. remains at the forefront of creating sustainable solutions that not only convert waste into valuable products but also advocate the principles of a circular economy. oceansix’s unwavering commitment to sustainability is intensified by its strategic alliance with RePack, magnifying its impact on global environmental challenges.

About RePack

RePack is more than just another reusable packaging supplier; they’re pioneers in revolutionising the way businesses approach packaging. Rather than simply selling packaging repeatedly, RePack is dedicated to establishing efficient reuse systems that eliminate the need for companies to constantly replenish their packaging supplies.

RePack’s mission is clear: to provide innovative reusable packaging solutions that not only shrink the environmental footprint of deliveries but also elevate the overall customer experience.

Disclaimer

This press release might include forward-looking statements based on current expectations and projections about future events. Generally, forward-looking statements and information may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, "plans", "believes", "seeks", "estimates" or "will". These are subject to risks, uncertainties, and changes in circumstances that may cause actual results to differ materially from those expressed or implied by such statements. In this press release, forward looking statements include statements regarding reducing the reliance on single-use packaging in e-commerce deliveries; the issuance of the balance of Shares; and receiving Exchange approval for closing the Acquisition. oceansix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Approval & Accuracy

Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) assumes responsibility for the adequacy or accuracy of this press release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515940303/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye